Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Keene

Podiatrist, Primary Podiatric Medicine Rockford, IL Doctor of Podiatric Medicine

NPI 1508967621 CMS profile 67899

4777 E State St, Ste 8, Rockford, IL 61108

Open in the dashboard

General payments

$1,403

28 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Keene of Rockford, IL is reported in the CMS Open Payments database as having received $1,403 across 28 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Podiatrist, Primary Podiatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $368 5
2024 General $183 3
2023 General $375 5
2022 General $12 1
2021 General $331 6
2020 General $72 4
2019 General $62 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Keene
  • Podiatrist, Primary Podiatric Medicine median
  • Middle half of Podiatrist, Primary Podiatric Medicine
  • National median

In program year 2025, general payments to Matthew Keene were reported at $368. Among 368 Podiatrist, Primary Podiatric Medicine profiles paid that year, the median was $232 and the middle half received between $88 and $586.

Show as a table
Year Matthew Keene Podiatrist, Primary Podiatric Medicine median Middle half National median
2019 $62 $166 $51–$513 $163
2020 $72 $108 $33–$249 $114
2021 $331 $147 $52–$377 $132
2022 $12 $188 $66–$551 $149
2023 $375 $195 $70–$509 $160
2024 $183 $209 $59–$508 $164
2025 $368 $232 $88–$586 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $428 10 payments
  2. Treace Medical Concepts, Inc. $226 1 payment
  3. Smith+Nephew, Inc. $218 2 payments
  4. Linvatec Corporation $112 1 payment
  5. Surgenex LLC $92 2 payments
  6. Integra LifeSciences Corporation $77 1 payment
  7. Medline Industries, Inc. $63 1 payment
  8. Zimmer Biomet Holdings, Inc. $48 2 payments
  9. Flower Orthopedics Coporation $36 1 payment
  10. Wright Medical Technology, Inc. $35 3 payments
  11. Other $68 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,403 28 payments
Products named General payments · program years 2019–2025
  1. TMC NANOPLASTY SYSTEM $226 1 payment
  2. GRAFIX PL $218 2 payments
  3. AUGMENT INJECTABLE $148 3 payments
  4. INFINITY ADAPTIS $112 1 payment
  5. COLINK PLATING SYSTEM $112 1 payment
  6. FRACTURE AND CORRECTION COLAG 2 $112 1 payment
  7. ORTHOLOC 2 LAPIFUSE $93 2 payments
  8. SurGraft $92 2 payments
  9. SurMatrix $92 2 payments
  10. ArdeoGraft $92 2 payments
  11. Other $851 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

430

Median for Podiatry: 160

Drug cost

$3,837

Median for Podiatry: $2,368

Branded share of claims

48.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clotrimazole Generic 39 $882
Gabapentin Generic 50 $741
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 76 $639
Diclofenac Sodium Generic 20 $477
Acetaminophen-Codeine Acetaminophen With Codeine Brand 46 $295
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 36 $210
Triamcinolone Acetonide Generic 37 $183
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 51 $157
Methylprednisolone Generic 28 $138
Tramadol Hcl Generic 30 $62

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$162,109

Medicare's payments for the services billed

Medicare patients

764

Average age 76

Services billed

2,736

422 women, 342 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Arthritis 58%
Chronic kidney disease 44%
Ischemic heart disease 36%
Heart failure 34%
Depression 29%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Primary Podiatric Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record